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Bioactive alkaloids occupy an important position in applied chemistry and play an indispensable role in medicinal chemistry.
Amongst them, isoquinoline alkaloids like berberine, palmatine and coralyne of protoberberine group, sanguinarine of the
benzophenanthridine group, and their derivatives represent an important class of molecules for their broad range of clinical and
pharmacological utility. In view of their extensive occurrence in various plant species and signiﬁcantly low toxicities, prospective
development and use of these alkaloids as eﬀective anticancer agents are matters of great current interest. This review has focused
on the interaction of these alkaloids with polymorphic nucleic acid structures (B-form, A-form, Z-form, H
L-form, triple helical
form, quadruplex form) and their topoisomerase inhibitory activity reported by several research groups using various biophysical
techniques like spectrophotometry, spectroﬂuorimetry, thermal melting, circular dichroism, NMR spectroscopy, electrospray
ionization mass spectroscopy, viscosity, isothermal titration calorimetry, diﬀerential scanning calorimetry, molecular modeling
studies, and so forth, to elucidate their mode and mechanism of action for structure-activity relationships. The DNA binding of
the planar sanguinarine and coralyne are found to be stronger and thermodynamically more favoured compared to the buckled
structure of berberine and palmatine and correlate well with the intercalative mechanism of sanguinarine and coralyne and the
partial intercalation by berberine and palmatine. Nucleic acid binding properties are also interpreted in relation to their anticancer
activity.
1.Introduction
The mode of action of many drugs in clinical use for the
treatment of cancer, genetic disorders, and viral diseases is
believed to be based on their binding to nucleic acids and
subsequent modiﬁcation of the genetic material [1, 2]. The
discovery of the double helical structure of deoxyribonucleic
acid (DNA) by Watson and Crick in 1953 [3] and the
subsequent revelations relating to the structural features to
the basic functional properties of DNA such as replication
and transcription have proven the utility of DNA as a
potential target for the development of biologically active
agents [4, 5]. Ribonucleic acid (RNA) also play essential role
i nn o r m a lb i o l o g i c a lp r o c e s sa sw e l la si nt h ep r o g r e s s i o n
of many diseases that led to growing interests in exploiting
in designing of new class of therapeutics [6–8]. A number
of small organic molecules are endowed with cytotoxic
properties that are exerted through highly speciﬁc but
noncovalent and reversible interactions with nucleic acid
structures [9–13]. The noncovalent interactions are further
classiﬁed in terms of intercalation and groove binding.
Intercalation occurs when planar aromatic molecules are
sandwiched between two adjacent base pairs of nucleic
acids. Nonintercalative binding occurs in the major or
minor grooves of nucleic acids without inserting any part
of the binding molecule between base pairs. The physical
and molecular basis of binding of natural alkaloids to
nucleic acids has been a subject of extensive study in the
recent past [14–17]. Elucidation of the nature, strength and
energetics of these interactions may reveal the molecular
basis of many antitumor and antiviral natural products
and provide helpful guidance for rational drug design of
new potential chemotherapeutic agents. The intercalating
ligands constitute one of the most widely studied groups as2 Journal of Nucleic Acids
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Figure 1: Chemical structures of isoquinoline alkaloids.
they form important class of compounds for cancer therapy
[18]. In this context, considerable attention has been paid
to naturally occurring protoberberine and benzophenan-
thridine alkaloids for their low toxicity and wide range of
biological activities that include antimicrobial, antileukemic,
anticancer, and topoisomerase inhibitory activities [19–26].
This review focuses on the complex formation of two groups
of isoquinoline alkaloids with various polymorphic nucleic
acid structures in relation to their anticancer activities.
These alkaloids (Figure 1) include berberine, palmatine, and
coralyne of the protoberberine group, sanguinarine of the
benzophenanthridine group, and some of their derivatives.
2. NucleicAcid BindingAspects of
BioactiveIsoquinolineAlkaloids
It is generally recognized that the most sensitive target
for the inhibition of rapidly proliferating cancer cells are
those molecules involved in aspects of DNA function,
especially DNA itself. It is, therefore, not surprising that
most clinically useful anticancer compounds act against
such targets. In this context, signiﬁcant attention has been
focused on the DNA binding properties of protoberberine
group of alkaloids that constitute an important class of
isoquinoline alkaloids widely present as active constituents
of folk medicines used world over for centuries. Several
protoberberine alkaloids and their derivatives have been
investigated as potential antitumor agents, among which
berberine, palmatine, and coralyne (a synthetic analogue of
berberine) represent the most intensively studied molecules.
The physicochemical properties of protoberberine alka-
loids presented in Table 1 provide an understanding of
the similarity and diﬀerences in their chemical structures
(Figure 1) and properties. The basic skeleton of the qua-
ternary protoberberine moiety is 5,6-dihydro[a,g] quino-
lizinium [29]. In berberine, there is an addition of 2,3-
methylenedioxy and 9,10 dimethoxy group to the above
basic structure and thus the structure of berberine becomes
7,8,13,13a-tetrahydro-9,10-dimethoxy and 2,3 methylene-
dioxy berberinium. On the other hand, palmatine has
the same tetracyclic structure (7,8,13,13a-tetradehydro-9,10-
dimethoxy-2,3, methylene dioxy berberinium) as berberine
but diﬀers by the nature of the substituents at position
2,3 on the benzo ring; being dimethoxy for palmatine.
Similarly coralyne has the basic structure with a methyl
group attached to the C8 position. Notably, while berberine
and palmatine have buckled structures, coralyne has a planar
structure. In aqueous condition, the absorption spectra of
berberine and palmatine are similar while that of coralyne
is remarkably diﬀerent. Both berberine and palmatine have
weak intrinsic ﬂuorescence emission spectra while coralyne
has a strong ﬂuorescence emission spectrum in aqueous
and alcoholic media. Berberine, palmatine, and coralyne
are achiral molecules as evidenced from circular dichroism
spectroscopy.SanguinarineisthemostimportantmemberofJournal of Nucleic Acids 3
Table 1: Some physicochemical properties of isoquinoline alkaloids [15, 16, 27, 28].
Properties Berberine Palmatine Coralyne Sanguinarine
(iminium form)
Empirical formulae C20H18O4N+ C21H22O4N+ C22H22O4N+
Chemical name
7,8,13,13a-tetradehydro-
9,10-dimethoxy-2,3-
methylenedioxy
berberinium
7,8,13,13a-
tetradehydro-
2,3,9,10-
tetramethoxy-
berberinium
5,6,7,8,13,13a-
hexadehydro-8-methyl-
2,3,10,11-tetramethoxy
berberinium
C20H14O4N+(13-
methyl
[1,3]benzodioxolo
[5,6-c]-1,3-
dioxolo[4,5-i]-
phenanthridium(1+)
Crystal colour Yellow Canary yellow Dark yellow Chloride salts are
orange red
Solubility Water Water Ethanol Salts are soluble in
water
Molecular weight (ion) 336.36 352.50 364.42 332.33
Melting point (◦C) 210 (chloride salt) 221 (chloride salt) 250–252 (chloride salt) 277–280◦C
Peak position of absorption
spectrum (nm)
230, 267, 344 and 420
(in aqueous buﬀer)
232, 268, 344.5 and
420 (in aqueous
buﬀer)
219, 231, 300, 311 326,
360, 405, and 424 (in 30%
ethanol) 219, 231, 300, 311
326, 360, 405, and 420 (in
aqueous buﬀer)
273, 327, 400 and
475nm (in aqueous
buﬀer of pH 5.5)
Molar extinction coeﬃcient
(ε)( M −1 cm−1) 22,500 at 344nm 25,000 at 344nm
14,500 at 420nm (in
aqueous buﬀer) and
17,500 at 424nm (30%
alcohol)
30,700M−1 cm−1 at
327nm in 0.1NHCl
Peak position of ﬂuorescence
emission spectrum
Very weak, at 530nm
(λex 350nm)
Very weak, at 530nm
(λex 350nm)
Strong, at 470nm (both in
aqueous and alcoholic
media) (λex at 424nm)
at 580nm (λex 327
or 475nm)
Optical rotation [α]D (solvent) 0◦(H2O) 0◦(H2O) 0◦(in H2O and 30%
ethanol) 0◦(zero degree)
IC50 value (in mice) 27.5mg/Kg 65mg/Kg 40mg/Kg 19.4mg/Kg
the benzophenanthridine group. It exhibited pH dependent
structural equilibrium between the iminium (charged) and
the alkanolamine (neutral) forms with a pKa value of 7.4
[15]. Sanguinarine existed almost exclusively as iminium
and alkanolamine forms in the pH rang 1.0–6.0 and 8.5–
11.0, respectively. The characteristic uv-vis absorption and
ﬂuorescence spectra of each form were studied [15]. One
interesting point to be noted is that the ﬂuorescence of
alkanolamine form is more intense than that of iminium
form. The iminium form is unsaturated and completely
planar while alkanolamine form has buckled structure.
Both forms are achiral. Some physicochemical properties of
sanguinarine are given in Table 1.
2.1. Alkaloid-DNA Interaction. The most convenient tool for
detecting the complex formation between nucleic acids and
smallmoleculesisabsorbancespectra.Likemanyothersmall
molecules that bind nucleic acids, berberine has by virtue of
heterocyclic structure visible absorption band where DNA
does not contribute and hence is convenient to monitor
the binding. The complex formation essentially involves
bathochromic and hypochromic eﬀect on its absorption
spectrum with clear isosbestic points indicating the onset
of equilibrium binding. The bathochromic shift of the spec-
trum of the free alkaloid on interaction with DNA indicates
the binding of individual alkaloid to DNA substrate, that
is, no aggregation prevails [35]. Moreover, such red shift
presumablyarisesfromthestrongintermolecularinteraction
involving the eﬀective overlapping of the electronic cloud of
the base pairs of DNA with that of the alkaloid. Again, the
less polar environment of the bound ligand can cause the
hypochromic eﬀect on the free absorption spectrum of the
ligand and intercalative positions are hydrophobic in nature.
A large number of studies reported the complexation of
berberine with calf thymus DNA possibly by a mechanism
of partial intercalation [15, 16] and references therein.
Maiti et al. [30, 36–38] have ﬁrst demonstrated the base
and sequence speciﬁcity of berberine from studies with
several naturally occurring and synthetic DNAs of diﬀer-
ing base composition and sequences as evidenced from
hypochromism and bathochromism in the absorption spec-
trum (Figure 2), remarkable enhancement of steady-state
ﬂuorescence emission intensity, stabilization of DNA against
thermal denaturation, and perturbation in the circular
dichroism spectrum. Berberine increased the contour length
of sonicated rod like duplex B-DNA depending on base
composition and induced the unwinding-rewinding process
of covalently closed superhelical DNA with an unwinding
angle of 13◦. Using high-ﬁeldNMR, Saran et al. [39]ﬁ r s t
proposed that berberine binds to double helical calf thymus4 Journal of Nucleic Acids
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Figure 2: Absorption spectrum (1) of berberine (8μM) with
increasing concentration up to 117.6μM (7) and 125.0μM( 8 )o f
calf thymus DNA. Reprinted from the Ph.D. Thesis of Bhadra [28].
DNA by a mechanism of partial intercalation in which the
planar isoquinoline moiety remained intercalated between
base pairs. The partial intercalation model was further sub-
stantiated from several analytical techniques that included
absorption, ﬂuorescence, isothermal titration calorimetry,
diﬀerential scanning calorimetry, electrospray ionization
massspectroscopy,incombinationwithcomputermolecular
modeling studies [27, 40–43] .H o w e v e r ,aﬂ u o r e s c e n c e
spectral study of berberine with calf thymus DNA [44]a n d
a high-resolution 1HNMR and UV spectroscopy [45]i n
conjunction with molecular modeling studies on berberine
binding to various short oligonucleotide duplexes (B-form)
favoured a groove binding geometry. This suggested that
berberine is located in the minor groove with a preference
for AT sequences, lying with the convex side on the helix
groove where the positively charged nitrogen atom is close
to the negative ionic surface of the oligonucleotide helices.
Zhu et al. [46] supported the interaction of berberine with
B-DNA by partial intercalation in which isoquinoline part
intercalated in presence of β-cyclodextrin. However, Chen
et al. [47] studied the interaction of berberine with sev-
eral double stranded oligonucleotides [d(AAGAATTCTT)2,
d(AAGGATCCTT)2, and d(AAGCATGCTT)2 using electro-
spray ionization mass (ESI-MS) and ﬂuorescence spectro-
scopic techniques to establish the sequence selectivity and
preference of binding to these structures. The results from
ESI-MS and ﬂuorescence titration experiments indicated
that the sequence selectivity of berberine was not signiﬁcant
and remarkable AT rich DNA binding preference was not
observed.
It is known that alternating GC polymer and its methy-
lated analogue structures assumes left-handed conformation
(Z-DNA) in high molar salt (Na+,K +), in low molar divalent
cations (Ca2+,Mg 2+,Ni 2+), micromolar concentration of
hexamine cobalt chloride, and millimolar concentration of
polyamines. In order to analyze the binding of berberine
to Z-form DNA, Kumar et al. [49] reported that Z-DNA
structure remained invariant in the presence of berberine up
to a nucleotide phosphate /alkaloid molar ratio of ∼0.8 and
suggested that berberine neither bound to Z-form DNA nor
converted the Z-DNA to the bound B-form structure like
other intercalators [15].
The molecular architecture of the HL-from DNA appears
to be unique, stable left-handed structure with Hoogsteen
base pairs, is distinctly diﬀerent from the right-handed B-
DNA and left-handed Z-DNA [15, 16]. The binding of
berberine to HL-DNA was found to be non-cooperative
resulting in perturbation of the circular dichroism spectrum
and generation of extrinsic circular dichroism bands with
opposite sign and magnitude compared to the B-form DNA
[49]. It was suggestedthat berberine could be used as a probe
to detect the alternation of structural handedness due to
protonation andmaypotentiate its usein regulatoryrolesfor
biological functions.
The formation of intermolecular triplex oﬀers a means
of achieving sequence speciﬁc recognition of duplex DNA
forming speciﬁc hydrogen bonds. Although the third
strand oligonucleotide possesses speciﬁc sequence recog-
nition properties, the binding is not so strong which
results in a relatively low stability of the triplex structure.
The instability of triple helical structures under normal
physiological conditions is a critical limitation that restricts
theirusesinvivo.Severalintercalatingligandshavenowbeen
reported that can preferentially stabilize triplex structures
[50–55]. Ren and Chaires [50] have shown that berberine
preferentially and very strongly bound to TxA.T triplex
compared to AT duplex using novel competition dialysis
and thermal melting experiments. Recently Das et al. [48]
demonstrated that berberine stabilized the Hoogsteen base-
paired third strand of TxA.T triplex without aﬀecting the
Watson-Crick strands as revealed from thermal melting
(Figure 3(a)) and circular dichroic studies (Figure 3(b))a n d
proposed that it binds to the third strand presumably by
mechanism of intercalation. Thermodynamics of berberine-
triplex complexation revealed that the binding process was
exothermic and entropy driven favouring a tight binding at
the intercalation site [48].
In recent years, recognition that certain sequences pro-
mote formation of higher-order structures of DNA has
revealed new targets for chemotherapy [58–60]. These
structures can form the association of four single strands
containing tracts of guanine bases (tetramer), and can also
arise within one or two strands containing several of these
sequences as the strands fold back upon themselves. In
order to understand the potential of quadruplex DNA as
a chemotherapeutic target, it is important to understand
the role and occurrence of telomeres in cells. Guanine rich
sequences with the ability to form quadruplex structures are
f o u n di nt e l o m e r e sa tt h ee n do fe u k a r y o t i cc h r o m o s o m e s
(TTAGGG repeats in humans) as well as in promoter regions
of genes and in recombination sites [61, 62]. Telomeres are
pieces of DNA that are extensions of linear chromosomes
[63]. The observations that telomerase is expressed inJournal of Nucleic Acids 5
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Figure 3: (a) The thermal melting proﬁle of poly(dT)·poly(dA)xpoly(dT) triplex (-•-) and its complex with berberine at alkaloid/DNA
ratio of 0.1 (-O-) and 0.3 (--). (b) Circular dichroic spectrum (1) of the same triplex (48.8μM) with increasing concentrations up to
(31.05μM) of berberine (9). Reprinted in part from Das et al. [48] with permission from 2003 Adenine Press.
Table 2: Comparative binding parameters of interaction of various alkaloids with calf thymus DNA and covalently closed superhelical DNA.
Alkaloid Ka (×105 M−1) n ΔTm
b (◦C) βc θd References
Berberine 0.38 4.0 7.0 1.35 12.6 [28, 30]
13.0
Palmatine 0.19 4.0 11.0 1.40 15.0 [28, 31]
Coralyne 1.0 9.0 12.0 1.62 21.0 [28, 32]
18.0
Sanguinarine 9.45 3.4 21.3 1.86 27.0 [33, 34]
aK the intrinsic binding constant determined using equation r/Cf = K(1 − nr)[(1 −nr)/(1 −(n −1)r)]n−1,w h e r er is the number of alkaloid molecules
bound per mole of nucleotide and Cf is the molar concentration of free alkaloid, where n denotes the binding site size in base pairs.
bΔTm is the Tm of the DNA in the presence of alkaloid-Tm of the free DNA.
cβ value was calculated from the slope, when L/Lo or (η/η0)1/3 is plotted against r using the equation L/Lo = (η/η0)1/3 = 1+βr,w h e r eL and Lo are the
contour length of helix in presence and absence of ligand corresponding values of intrinsic viscosity (approximated to the reduced viscosity) of the solution
and r is the mole ligand bound /mole nucleotides.
dunwinding angle.
malignant but not normal tissues led to the paradigm that
drugs that interfere with the action of telomerase could be
expected to cause the death of cancer cells. If interactions
of telomeric proteins with speciﬁc sequences of telomeric
DNA are lost, this also leads to cell death by apoptosis
[64]. This suggests that compounds that bind to DNA and
inhibit protein binding would cause the rapid death of
tumor cells. Compounds that stabilize quadruplex DNA,
presumably preventing interactions with proteins have been
shown in vitro to inhibit telomerase [65]. Recent studies
show that berberine inhibits telomere elongation [66]a n d
binds strongly to various G-quadruplex DNA structures and
inhibits telomerase activity [50, 67]. Thus berberine may
be used as a target to probe for G-quadruplex DNA for its
development as potential antitumor drugs.
Palmatine is structurally similar to the well-known
isoquinoline alkaloid berberine. To evaluate the aﬃnity
and mode of binding to B-DNA, Kluza et al. [69]a n d
Bhadra et al. [31] reported that addition of calf thymus
DNA caused marked changes in the absorption spectrum
of palmatine (Figure 4) with strong hypochromic and
bathochromic shifts, with well-resolved isosbestic points,
and with increased thermal melting temperature to form
stable complexes with B-DNA. Further from electric linear
dichroism studies, it was interpreted that palmatine binds
either by an intercalation or by an external stacking parallel
to the base pairs. However, an earlier study by Yu et al. [70]
proposed a nonintercalative binding of palmatine. Recently,
the author’s laboratory [56] demonstrated the base and
sequence-dependent binding of palmatine and established
that palmatine formed a partial intercalation complex with
all the polymers except the homo and heteropolymer of
GC, with which it formed a nonintercalative complex. The
binding of palmatine to calf thymus DNA was further
characterized by thermodynamic studies using isothermal
titrationcalorimetryandthebindingprocesswasexothermic6 Journal of Nucleic Acids
Table 3: Thermodynamic parameters for the interaction of various alkaloids with calf thymus DNA complexation obtained from isothermal
titration calorimetric studiesa.
Alkaloid K (×105 M−1) n ΔG◦ (kcal mol−1) ΔH◦ (kcal mol−1) ΔS◦ (cal·deg−1 mol−1) References
Berberine 0.12 3.6 −5.50 −2.01 +11.40 [28, 42]
Palmatine 0.28 3.0 −5.82 −4.40 +5.00 [28, 56]
Coralyne 71.54 .0 −9.25 −7.05 +7.70 [28, 42]
Sanguinarine 9.52 2.2 −8.02 −6.91 +3.70 [57]
aAverage of four determinations, K and ΔH◦ v a l u e sw e r ed e t e r m i n e df r o mﬁ t so ft h eI T Cp r o ﬁ l e st oO r i g i n7 . 0 .T h ev a l u e so fΔG◦ and ΔS◦ were determined
using the equations ΔG◦ =− (RT lnK)a n dΔG◦ = ΔH◦ − TΔS◦. respectively. The ITC proﬁle was ﬁt to a model of single binding sites, where n denotes the
binding site size.
Table 4: Spectroscopic and thermodynamic parameters for the interaction of various alkaloids with DNA triple helical structure with
referencesa.
Complexes Ka n ΔTm
b ΔG
◦ ΔH
◦ ΔS
◦ References
(×105 M−1)( ◦C) (3 → 2) at rmax kcal mol−1 kcal mol−1 cal·deg−1 mol−1
Poly(dT)·poly(dA)xpoly(dT)+berberine 3.2 6.4 7.80 −7.35 −4.61 +9.52 [48]
Poly(dT)·poly(dA)xpoly(dT)+coralyne dna dna 19.0 dna dna dna [68]
Poly(dT)·poly(dA)xpoly(dT)+sanguinarine 26.0 3.3 24.5 −8.56 −4.14 +15.11 [48]
Poly(dC)·poly(dG)xpoly(dC+)+sanguinarine 16.0 2.5 7.50 −8.28 −10.73 −8.36 [48]
aK (the intrinsic binding constant) determined using equation r/Cf = K(1 − nr)[(1 −nr)/(1 −(n −1)r)]n−1,w h e r er is the number of alkaloid molecules
bound per mole of nucleotide and Cf is the molar concentration of free alkaloid.
bΔTm (3 → 2) is the Tm of the triplex DNA in the presence of alkaloid-Tm of the free triplex DNA. (3 → 2) denotes the transition temperature from triplex
complex to duplex complex formation.
∗dna: data not available.
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Figure 4: Absorption spectrum (1) of palmatine (7.6μM) with
increasing concentrations up to 151.6μM (11) and 175.2μM (12)
of calf thymus DNA. Reprinted from the Ph.D. Thesis of Bhadra
[28].
and entropy-driven which favour the intercalative mode of
binding. It does not bind to Z-DNA nor does it convert Z-
form to B-form. Unlike berberine, palmatine showed very
weak binding to HL-form. To date there is no report on
the binding of palmatine to higher-order DNA structures,
triplexes, and quadruplexes and study in this direction is
awaited.
Another important alkaloid of protoberberine group is
the synthetic molecule coralyne, which was found to be
potentially capable of intercalating with B-DNA [32, 73,
74] and the results led to the assumption that the DNA
binding may be correlated with biological activity. It was
r e p o r t e dt h a ta tal o w e rm o l a rr a t i oo fc o r a l y n et oB -
DNA, an intercalating complex by π stacking along the
backbone of DNA, while at higher molar ratios, a DNA-
induced aggregation occurred [73]. Although a wealth of
data [32, 73, 74] is presently available regarding the complex
formation between coralyne and B-DNA, the interpretation
of these data needs to be performed with caution as coralyne
exhibits a high tendency of aggregation in aqueous buﬀer
even at very low concentrations. Maiti et al. [32]ﬁ r s t
addressed this problem and showed that aqueous solutions
containing 30% (v/v) ethanol suppressed the aggregation
of coralyne and allowed spectrophotometric titration of
a fully monomeric form with calf thymus DNA. The
base and sequence speciﬁcity of coralyne (monomeric) on
binding to various naturally occurring and synthetic B-DNA
were studied by spectrophotometric and spectroﬂuorimetric
titrations, circular dichroic spectroscopy, thermal melting,
isothermal titration calorimetry, and viscometric studies.
The results of spectrophotometric and calorimetric studies
of a fully monomeric form of coralyne with calf thymus
DNA is presented in Figures 5(a) and 5(b),r e s p e c t i v e l y .
Coralyne increased the contour length of sonicated rod like
duplex B-DNA and induced the unwinding and rewinding
process of covalently closed superhelical B-DNA with an
unwinding angle of 21◦. These experiments revealed that
monomeric coralyne binds to B-DNA by a mechanism
of intercalation with a relatively high speciﬁcity towardJournal of Nucleic Acids 7
1
10.11
370 400 450 500
Wavelength (nm)
0
0.04
0.08
0.12
0.16
A
b
s
o
r
b
a
n
c
e
(a)
00 .20 .40 .6
Molar ratio
−8
−6
−4
−2
0
I
n
j
e
c
t
a
n
t
(
k
c
a
l
/
m
o
l
e
)
−0.2
−0.1
0
(
μ
c
a
l
/
s
)
0 20 40 60 80 100
Time (min)
(b)
Figure 5: (a) Absorption spectrum (1) of coralyne (7.09μM) with increasing concentrations up to 81.73μM (10) and 96.28μM (11) of calf
thymus DNA. (b) The ITC proﬁles for the titration of calf thymus DNA (65μM) to coralyne (15μM) at 20◦C. Each heat burst curve in the
upper panel is the result of a 5μL injection of DNA into coralyne. The lower panel represents the corresponding normalized heat signals
versus molar ratio. The data points reﬂect the experimental injection and the solid line represents the best ﬁt of the data. Reprinted from the
Ph.D. Thesis of Bhadra, [28].
Table 5: Eﬀect of berberine incubated with S180 cells in vitroa.
Pathway Percent control
4μg/mL 40μg/mL
Glycine → [14C] Protein 2.9 0.1
Thymine → [3H] DNA 48.9 1.6
Uridine → [3H] RNA 13.4 0
a Data obtained from W. A. Creasey [80].
alternating GC sequences. Comparative spectroscopic and
thermodynamics binding parameters for the interaction of
isoquinoline alkaloids with calf thymus DNA are presented
in Tables 2 and 3, respectively. Recently, it has been reported
[28, 75] that coralyne, unlike other classical intercalators,
binds to Z- form DNA without converting the bound form
to the B-form bound structure as revealed from circular
dichroic spectroscopy. Studies indicated that coralyne could
be used as a probe to detect the Z-form structure in
vivo [28]. Coralyne showed strong perturbation of circular
d i c h r o i cs p e c t r u mo fH L-form DNA (Figure 6). However,
the mode and mechanism of binding of coralyne-HL-DNA
complexation could not be revealed from these studies.
In addition, coralyne was shown to bind to parallel
triplex DNA but it does not bind to antiparallel triplex
DNA [53]. It was concluded from early experiments using
thermal denaturation analysis and spectrophotometric titra-
tion with TxA.T and CxG.C+ containing DNA triplexes that
coralyne does not exhibit signiﬁcant sequence selectivity
during triplex complexation [68]. A later study, however,
using various techniques like DNase foot printing, ther-
mal denaturation analysis, spectrophotometric titration and
circular dichroic, as well asNMR spectroscopy, showed a
preferential intercalation of coralyne into TxA.T triplexes
[81], whereas in CxG.C+ triplexes, the coralyne molecule
was only partially intercalated due to the electronic repulsion
between the cationic alkaloid and protonated cytosine. The
high propensity of coralyne to stabilize triplex DNA has been
demonstrated by Hud et al. [55, 82] from the observation
thatduplexpoly(dT)·poly(dA)istransformedintoamixture
of poly(dT)xpoly(dA)·poly(dT) triplex and single stranded
poly(dA) in presence of coralyne at slightly elevated tem-
perature (T>37◦C). This disproportionation reaction of
double-stranded DNA has been rationalized in terms of the
formation of a highly stable intercalation complex between
coralyne and triplex DNA. Further, they demonstrated that
coralyne may act as a template for the formation of an
antiparallel DNA triplex from homoadenine sequences [83].
Coralyne was found suitable for stacking interactions with
G-quadruplex [67]. In this study it was shown that coralyne
has the ability to induce and stabilize various G-quadruplex
structures including human G-quadruplex as well as its eﬃ-
ciency in inhibiting telomerase. The thermal stabilization of
a preformed intermolecular G-quadruplex structure shows8 Journal of Nucleic Acids
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Figure 6: Circular dichroic spectrum of (1) H
L-DNA (20μM)
with increasing concentrations up to (20.64μM) of coralyne (10).
Reprinted from the PhD Thesis of K. Bhadra, [28].
that coralyne and berberine is able to stabilize rather than
to induce G-quadruplex intermolecular structure. In both
cases, coralyne is the most active component possibly due to
its fully aromatic core and it is the most eﬃcient telomerase
inhibitor.
Among the benzophenanthridine alkaloids, sanguinar-
ine, an isoquinoline plant alkaloid, is known to generate
a wide variety of biochemical and pharmacological eﬀects
including its use in cancer prevention. The physical and
molecular basis of the binding of sanguinarine with canoni-
calB-DNAwereﬁrstdemonstratedbyMaitietal.[33,34,84–
88] using various physicochemical techniques like absorp-
tion, ﬂuorescence, circular dichroism, thermal melting, vis-
cometry, calorimetry, andNMR spectroscopy. On binding to
B-DNA structures, the absorption spectrum of sanguinarine
underwentbathochromicandhypochromicchangesexhibit-
ing clear isosbestic points (Figure 7(a)), the steady-state
ﬂuorescence emission intensity quenched, thermal melting
temperature of B-DNA shifted to higher temperatures and
there were strong perturbations of circular dichroic pattern
of B-DNA. Sanguinarine induced the unwinding process
of covalently closed superhelical plasmid B-DNA with an
unwinding angle of 27◦. The binding of sanguinarine to calf
thymus DNA was also investigated [39]b y1HNMR and all
the proton resonances in the molecule were assigned using a
combination of 2D COSY, NOSEY, and ROSEY techniques.
All these experiments conclusively suggested that it binds B-
DNA by a mechanism of intercalation [39]. The intercalative
binding was subsequently supported by several authors
[89–92]. The sequence selective binding of sanguinarine
to B-DNA was also studied by Waring group [90] using
DNAse foot printing technique and a mixed nucleotide
sequence binding for sanguinarine-DNA complex formation
was proposed. Recent calorimetric studies of sanguinarine
calf thymus DNA complexation (Figure 7(b)) showed the
binding process to be exothermic and enthalpy driven [57].
Binding and thermodynamic parameters of sanguinarine—
calf thymus DNA complexation obtained from isothermal
titration calorimetry are presented in Table 3.Ar e c e n t
study [93] showed that sanguinarine also binds to single
pyrimidine bulges in hairpin sequences.
The interaction of sanguinarine with Z-DNA structure
was ﬁrst studied by Das et al. [94]. It was demonstrated that
on addition of the alkaloid to the Z-form structure, a direct
conversion of the Z-form toward the characteristic right-
handed bound complex without forming any intermediate
forms was observed. Sanguinarine bound strongly to B-
form in a noncooperative manner while its binding to Z-
form was highly cooperative and ∼2-3 base pairs of Z-
form switched to the right-handed form for each bound
sanguinarine molecule [94]. The interaction of sanguinarine
with HL-form showed that it does not bind to HL-form
structure, but it converted the structure to the bound right-
handed B-form [94, 95]. Here also approximately 2-3 base
pairs of the HL-form switched to the right-handed bound B-
form for each bound molecule of sanguinarine.
Latimer et al. [96] ﬁrst demonstrated that sanguinar-
ine binds to poly(dT)·poly(dA)xpoly(dT) but only weakly
to poly(dC)·poly(dG)xpoly(dC+) more quantitatively and
reported that sanguinarine binds to triplexes by inter-
calation in a noncooperative manner and it stabilized
the Hoogsteen base paired third strand of DNA com-
pared to their Watson-Crick strands. Thermodynamic study
revealed that the process of binding of sanguinarine to
poly(dC)·poly(dG)xpoly(dC+) triplex was exothermic and
enthalpy-driven while that to poly(dT)·poly(dA)xpoly(dT)
triplex was exothermic and entropy-driven. The binding
constants and thermodynamic parameters of berberine,
coralyne,andsanguinarinecomplexationtovarioustriplexes
are presented in Table 4. Recently, Bai et al. [97]r e p o r t e d
that sanguinarine can form a complex with G-quadruplex
telomere DNA as revealed from DNA polymerase stop assay,
uv melting, electrospray mass spectroscopy, and circular
dichroism studies which may potentiate a strategy for
structure-based anticancer drug design targeting human
telomeres.
2.2. Alkaloid-RNA Interactions. RNAs are versatile molecules
that are now known to play an essential role in normal
biological process and in the progression of several serious
human diseases like HIV and Hepatitis C virus (HCV), and
so forth which has led to growing interest in exploiting RNA
as a cellular target for therapeutic drug design. The recent
discovery of a number of micro RNAs and the knowledge
of their functions further reiterated the critical and diverse
roles played by RNA in cell biology [98, 99]. Ribosomal
RNA (r-RNA) has long been known to be the receptor for
antibiotics and antisense oligonucleotides are being used
to downregulate gene expression [100]. New drugs could
potentially be designed to bind to unique structural regions
in mRNA and thereby regulate gene expression. VirtuallyJournal of Nucleic Acids 9
1
1
6
6
300 350 450 550
Wavelength (nm)
0
0.05
0.1
0.15
A
b
s
o
r
b
a
n
c
e
(a)
00 .511 .5
Molar ratio
−6
−4
−2
0
I
n
j
e
c
t
a
n
t
(
k
c
a
l
/
m
o
l
e
)
−0.2
−0.1
0
(
μ
c
a
l
/
s
)
(b)
Figure 7: (a) Absorption spectrum (1) of sanguinarine (4.9μM) with increasing concentrations up to 54.8μM (10) of calf thymus DNA.
Reprinted from the PhD Thesis of A. Das [71]. (b) The ITC proﬁles for the binding of sanguinarine (100μM) to Calf thymus DNA (15μM).
The lower panel represents the corresponding normalized heat signals versus molar ratio. The data points reﬂect the experimental injection
and the solid line represents the best ﬁt of the data. Reprinted from the Ph.D. Thesis of Hossain [72].
all mRNAs formed in eukaryotic cells have a poly(A) tail
of approximately 200–250 adenosines at the 3’end. The
long poly(A) tail is an important determinant of mRNA
stability and maturation, and is essential for the initiation
of transcription [101, 102] and the production of alternate
forms of proteins [103, 104]. The structure of poly(A) has
been established to exist as a single-stranded helix stabilized
by pair-wise stacking interaction between adjacent adenines
at physiological pH and temperature [105, 106]. Poly(A)
polymerase (PAP) catalyses 3’-end poly(A) synthesis, par-
ticipates in an endonucleolytic cleavage step and is one of
the key factors in polyadenylation of the 3’end of mRNA.
Neo-PAP, a recently identiﬁed human PAP, is signiﬁcantly
overexpressed in human cancer cells in comparison to its
expression in normal or virally transformed cells [107, 108]
and may represent a tumor-speciﬁc target. Small molecules
capable of recognizing and binding to the mRNA-poly(A)
tailmightinterferewithfullprocessingofmRNAbyPAPand
would represent a new type of potential therapeutic agent. In
this context, several years ago Maiti et al. [76]ﬁ r s to b s e r v e d
a preferential binding of berberine to poly(A) structure
over B-DNA and tRNA and reported that the binding
aﬃnity of berberine to poly(A) was approximately 12 times
higher than B-DNA and approximately 100 times higher
than t-RNA molecules. Recently, they investigated the mode,
mechanism, and energetics of berberine binding to poly(A)
structure in details [109]. It was suggested that berberine
binds strongly to single-stranded poly(A) structure by a
mechanism of partial intercalation and the binding was
found to be endothermic and entropy driven. Giri et al.
[77] studied the interaction of palmatine with poly(A) using
various biophysical techniques and their results also showed
as t r o n ga ﬃnity of palmatine to poly(A). The energetics of
this strong binding of palmatine to poly(A) was found to be
exothermic and enthalpy-driven [77].
Xing et al. [110] showed that coralyne binds to single-
stranded poly(A) helix and induced the formation of a
self-structure in poly(A). Depending on solution conditions
such as pH, salt and temperature, single-stranded poly(A)
can adopt a parallel double stranded conformation formed
by the pairing of adenine bases at the N1 position [111,
112]. The possibility of the formation of such a double
stranded poly(A) in eukaryotic cells was hypothesized to
result in the termination of the polyadenelation process
[113]. Small molecules that could bind strongly to single-
stranded poly(A) may be useful as potential leads for
controlling the mRNA-poly(A) chain elongation and in turn
mRNA degradation as well as the conversion of single-
stranded poly(A) to double stranded poly(A) that may open
up an opportunity for modulating nucleic acid structure-
functions. The plant alkaloids berberine and palmatine
exhibit stronger binding to single stranded poly(A), but do
not induce any self-structure formation in poly(A) helix
[109, 114]. Binding of coralyne to the poly(A) helix leading
to self structure formation was further supported by Giri
and Kumar [79] and the binding process was found to
be predominantly exothermic and enthalpy-driven with a
stoichiometry of one coralyne per four adenines bases.
Sanguinarine was also found to bind very strongly to
single stranded poly(A) [71, 78] and induce unique self-
structure in poly(A) [78]. The alkaloid binding process was
exothermic and predominantly enthalpy-driven as revealed
from isothermal titration calorimetry. Comparative circular
dichroic spectrum of poly(A) treated with various alkaloids10 Journal of Nucleic Acids
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Figure 8: Circular dichroic spectrum of poly(A) helix (solid line) treated with (a) berberine (dashed line), (b) palmatine (dashed line), (c)
coralyne (dashed line), and (d) sanguinarine (dashed line) at alkaloid/poly(A) molar ratio at saturation in each case. Partially reprinted from
Nandi et al. [76], Giri et al. [77], Giri and Kumar [78], and Giri and Kumar [79] with permission from Elsevier.
are shown in Figure 8. Spectroscopic studies showed that
amongthefouralkaloids,theaﬃnityofbindingofberberine,
palmatine, and coralyne to poly(A) helix is one order lower
than that of sanguinarine [116]. Thus, the very strong
binding of sanguinarine to poly(A) leading to self structure
formation may open up a new avenue for the use of this
natural product in modulating the gene expression and
development of anticancer agent.
3. Topoisomerase Activityof
MedicinalAlkaloids
Topoisomerasesarenuclearenzymesthatactonthetopology
of DNA. It was ﬁrst discovered by Wang [117]. There are
three main types of DNA topology; supercoiling, knotting,
andcatenation.Whenoutsideofreplicationortranscription,
DNA needs to be kept as compact as possible and these
three states help this cause. However, when transcription
or replication occurs, DNA needs to be free and these
states seriously hinder the process. DNA toposiomerases are
involved in the regulation of DNA supercoiling. Topoiso-
merase I (Topo I) changes the degree of supercoiling of
DNA by causing single strand breaks and religation whereas
topoisomerase II (Topo II) causes knotting, catenation and
decatenation of DNA by passing the double-stranded DNA
helix through a transient double-stranded break and then
resealing in the strand break [118, 119]. The diﬀerence roles
of DNA Topo I and II may indicate an opposing pair of roles
in the regulation of DNA supercoiling. Both activities are
especially crucial during DNA transcription and replication,
when the DNA helix must be unwound to allow proper
function of large enzymatic machinery. Recently, two more
topoisomerases have been discovered and these are namely
topoisomerase III and topoisomerase IV. Topoisomerase
III enzymes are implicated in regulation of recombinationJournal of Nucleic Acids 11
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events while topoisomerase IV has roles in the process of
segregating newly replicated chromosomes [120].
DNA topoisomerases Topo I and Topo II represent the
molecular target of many anticancer drugs. Fewer Topo
I inhibitors have been discovered than Topo II inhibitors
and a large number of them including the anthracyclines
have been used as anticancer agents before identiﬁcation of
Topo II as their target. These inhibitors are chemotherapy
agents designed to interfere with the action of topoisomerase
enzymes that control the changes in DNA structure by
catalyzing the breakage and rejoining of the phosphodiester
backbone of DNA strands during the normal cell cycle. In
recent years, topoisomerase inhibitors have become popular
targets for cancer chemotherapy treatments. It is thought
that topoisomerase inhibitors block the ligation step of the
cell cycle, and that Topo I and Topo II inhibitors interfere
with the transcription and replication of DNA by upsetting
proper DNA supercoiling. Topo I has been established as an
attractive molecular target for anticancer drugs, primarily
due to the discovery of camptothecin (CPT) a naturally
occurring plant alkaloid for its successful development as
an anticancer drug with a unique mode of action, that
is, inhibition of DNA Topo I, which added an entirely
new dimension to the ﬁelds of chemotherapy [121]. Thus,
developing compounds that are capable of poisoning the
topoisomerases have emerged as an attractive approach for
the search of novel cancer chemotherapeutic agents [122–
126]. For drugs [127, 128] that target Topo II intercalation
into the host DNA duplex is strongly correlated with enzyme
poisoning [129]. To understand the role that ligand-DNA
interactions play in Topo I poisoning Li et al. [130]h a v e
characterized and cross correlated the Topo I poisoning and
DNA binding properties of various families of structurally
related DNA binding protoberberine alkaloids (Figure 9).
T h e s ef o u ra n a l o g u e sd i ﬀer with respect to the chemical12 Journal of Nucleic Acids
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Figure 11: Chemical structures of several coralyne derivatives.
substituents on their A- and D-rings. Their DNA binding
data reveal that protoberberine alkaloids intercalate into
duplex DNA while unwinding the host DNA by 13◦.I n
addition, the data showed that modiﬁcation of the D-ring
alter both DNA binding aﬃnity and Topo I poisoning
activity. The modiﬁcations of the A-ring on the other hand
have a negligible impact on DNA binding aﬃnity but
exerted a profound inﬂuence on Topo I poisoning activity.
These structure-activity relationships are consistent with a
model for Topo I poisoning by protoberberines in which
both alkaloid-DNA and alkaloid-enzyme interactions are
necessary for stabilization of the ternary (Topo I-DNA-
alkaloid) cleavable complex (Figure 10). It is suggested that
an ensemble of both alkaloid-DNA and alkaloid-enzyme
interaction may be of general importance for alkaloid-
induced poisoning of Topo I.
Berberine, palmatine, and several of its derivatives were
shown to act as mammalian Topo I and Topo II inhibitors
although weakly [131], while coralyne and many of its
derivatives were found to be strong inhibitors of DNA Topo I
[132]. Both berberine and palmatine did not aﬀect the DNA
cleavage relegation reaction catalyzed by topoisomerases.Journal of Nucleic Acids 13
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Figure 12: Eﬀect of berberine on the incorporation of thymine
[3H] into DNA (-•-) and glycine [13C] into protein (--) by
sarcomaS180cancercellsinvitro.ReprintedfromCreasey[80]with
permission from Elsevier.
This lack of eﬀect most likely accounts for the presence of a
methoxy substituent at 9-position, which prevents hydrogen
bonding interactions with guanine residues. The 9-position
in berberine analogues is an important determinant for
DNAtopoisomeraseIIinhibition[131].Themostsigniﬁcant
aspect of coralyne is its ability to inhibit DNA relaxation in
a fashion signiﬁcantly similar to the most potent antitumor
alkaloid CPT [133]. Wang et al. [134] demonstrated that
coralyne and several of its derivatives (Figure 11) including
the partially saturated derivative, 5,6-dihydrocoralyne (C2)
were tested for their ability to induce single-stranded cleav-
age by formation of ternary complexes with plasmid DNA
and Topo I. It was observed that all the derivatives (C1–C11)
induced cleavage in plasmid DNA but are not as eﬀective
as coralyne (C1) or 5,6-dihydrocoralyne (C2) and stabilize
the complex between Topo I and DNA. However, coralyne
(C1)w a sm o r ee ﬀective than 5,6-dihydrocoralyne (C2)a t
lower concentration. In a subsequent study, Pilch et al. [40]
conﬁrmed that 8-desmethylcoralyne (C3) and 5,6-dihydro-
8-desmethylcoralyne (C11)m a ya c ta sT o p oIp o i s o n ,
whereas no Topo II poisoning properties were observed.
More recent immunocytochemical studies in MCF-7 breast
cancer cells showed that sanguinarine induces a striking
disruption of normal cyclin and Topo II traﬃcking which
inhibited the proliferation of transformed cells [135].
4. Anticancer Properties of
IsoquinolineAlkaloids
Neoplastic disease is a global health problem. Although great
attention is currently focused in unraveling the molecu-
lar, cellular, and genetic process that lead to cancer, this
knowledge has not been translated into eﬀective new cures
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Figure 14: DNA damage of NCP/HK1 cells after 30 minutes.
Treatment of berberine at diﬀerent concentrations (5 to 200μM).
DNA damage was expressed in percentage of DNA content in
the Comet tails. The results are mean ± standard deviations of
three individual experiments. Reprinted from Szeto et al. [115]
with permission from the Turkish Journal Medical Science with
permission from the publishers.
for the disease. Recent report of American Cancer Society
(December 2007) showed that 7.6 million people died from
various types of cancers. Apart from humans, other animals
and plants may also be aﬀected by cancer. In general, cancer
deﬁnes diseases, in which abnormal cells divide without
control that have the capacity to invade surrounding normal
tissue, can spread to other parts of the body through
the blood and lymph systems and kill the host in which
it originates. For the last several years, it was observed
that the incidence of some types of cancer increases with
age. Therefore, as the life span of humans has increased,14 Journal of Nucleic Acids
(a) (b) (c)
Figure 15: NCP/HK1 cells cultured on culture disk were incubated with 200μM of berberine for 2 to 46 hours. (a) Cells treated for 2 hours;
(b) cells treated for 21 hours; (c) cells treated for 46 hours. Fluorescence indicated the presence of berberine. Reprinted from Szeto et al.
[115] with permission from the Turkish Journal Medical Science with permission from the publishers.
the incidence of neoplastic diseases has also increased. There
are several types of neoplastic diseases. Carcinoma is the
cancer that begins in the skin or in tissues that line or
cover internal organs. Sarcoma is the cancer that begins in
bone,cartilage,fat,muscle,bloodvessels,orotherconnective
or supportive tissue. Leukemia is the cancer that starts in
blood-forming tissue, such as bone marrow, and causes large
numbers of abnormal blood cells either produce or enter the
blood. Lymphoma and multiple myeloma are cancers that
begin in the cells of the immune system. Central nervous
system diseases are cancers that begin in the tissues of the
brain and spinal cord. Adrenocortical carcinoma disease is
cancer that forms in the outer layer of tissues of adrenal
glands. Breast cancer forms in tissues of the breast, usually
the ducts and lobules of women. Fibroids are common
tumors of the uterus (womb) found in about 20% of young
women and they form ball-like and may vary in size from
pin to very large size. Although noncancerous, they can
recur. Lung cancer is a disease that forms in tissues of the
lung, usually in the cells living air passages. Tobacco smoking
is associated with lung cancer and bladder cancer. Lung
cancer is one of the leading causes of cancer-related death
throughout the world. Despite of the advances in current
therapeutic approaches for lung cancer, including surgery,
radiotherapy, and chemotherapy, the overall survival rate of
the patients with lung cancer has been static for the past two
decades.
Improvement in curability and survival is dependent
on advances in early detection, surgery, radiotherapy, and
chemotherapy; but once widespread metastatic disease has
become established, chemotherapy is a central component
of management. Chemotherapy is the treatment of cancer
with drugs (anticancer drugs) that can destroy cancer cells.
In current usage, the term “chemotherapy” usually refers to
cytotoxic agents that aﬀect rapidly dividing cells in general
[136]. Several antitumor antibiotics and plant alkaloids
are the more recent clinically eﬀective antitumor cytotoxic
drugs, which act by disrupting the structure of duplex B-
DNA, thereby aﬀecting their interaction with proteins that
are important in DNA replication, repair, or transcrip-
tion. Investigation into the mechanism of action of plant-
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Figure 16: Time course of Smulow-Glickman (S-G) gingival
cells growth to a continuous three-day exposure to sanguinarine.
Cellular DNA was estimated with the ﬂuorochrome, Hoechst 33258
using an excitation wavelength of 360nm and emission wavelength
of460nm.ReprintedfromBabichetal.[137]withpermissionfrom
John Wiley and Sons Inc.
derived compounds with low toxicity remains an important
approach in the search for new and more eﬀective anticancer
agents.
Protoberberine and benzophenanthridine group of alka-
loids possessing broad range of biological activity [138–
146] are widely distributed in several botanical families and
are used in traditional Chinese and ayurvedic medicine for
many centuries. This review is restricted to their anticancer
properties currently studied in several laboratories. Berber-
ine is found in the roots of rhizomes of several families
of plants; Goldenseas, Coptin, Oregon grapes, Barberry, Tree
turmeric, Yerba mansa, among others and possess antitumorJournal of Nucleic Acids 15
activities [147, 148]. It exhibits potent in vitro antitumor
activity against Sarcoma S180 cells with inhibition of the
biosynthesis of DNA, RNA, and proteins [80]. It was evident
that berberine interfered with all these biochemical process
(Table 5). However, the synthesis of RNA and protein was
most sensitive to the alkaloid at 40 ug/mL. DNA and protein
biosynthesis were examined further by incorporation of
thymidine [3H] into DNA and glycine [14C] into protein
in S180 cells in vitro and dose response curves was shown
in Figure 12.C r e a s e y[ 80] reported that the in vivo 30-
minutes treatment with berberine on tumor bearing mice
(10mg/kg) before injection of thymidine [3H] or glycine
[14C] had only minimal eﬀects on the incorporation of
these precursors into DNA and protein, respectively, and
inhibition was found to be only 17% for protein and 14%
for DNA. However, when cells were harvested 30 minutes
after treatment with berberine and then incubated with
glycine [14C] and thymine [3H] in vitro incorporation into
protein and DNA (Figure 12) was reduced by 85% and 45%,
r e s p e c t i v e l y .K u oe ta l .[ 149]o b s e r v e da ni n c r e a s eo fG 2 / M
phase population in berberine-treated HL60 cells. It modu-
lates expression of mdr1 gene product in track cancer cells
[150] and was identiﬁed as a potential inhibitor for caspase
3, a major apoptosis eﬀector [151]. It was also reported
that berberine downregulates K-Ras 2 gene expression in
human embryonic carcinoma cells [152]. Apoptosis-induced
by berberine was found in cancer L1210 and U937 cells
[153]. Wu et al. [154] demonstrated that berberine-induced
apoptosis of human leukemia HL60 cells with downreg-
ulation of nucleophosmin/B23 and telomerase activity. Li
et al. [130] linked its cytotoxic activity to a duel Topo I
and Topo II poisoning activity. For management of skin
cancers, Montena et al. [155] for the ﬁrst time demonstrated
in vitro treatment of human epidermoid carcinoma A431
cells with berberine that decreased cell viability, induced
cell death in dose-dependent manner which was associated
with an increase in G1 arrest and suggested berberine to be
used as chemotherapeutic drug against human epidermoid
carcinoma A431 cells. The eﬀect of berberine on human
malignant brain tumor esopharyngeal cancer and human
leukemic and human colon cancer cell lines was tested,
where a signiﬁcant killing eﬀect was achieved [156, 157].
Subsequently, Szeto et al. [115] investigated the cytotoxicity
and the DNA damage eﬀect on NPC/HK-1 cells after
berberine treatment and evaluated the possibility of DNA
repair in this cell line. Their studies showed that berberine,
at 5–200μM induced cell death in a dose dependent manner.
Treatment of cells with 200μM berberine for 5 hours yielded
60% drop of cell viability (Figure 13). The Comet assay
was employed after berberine treatment (5 to 200μM). The
mean tail DNA content increased as berberine concentration
increased (Figure 14). DNA damage was evident within 30
m i n u t e sa n dw a sm o r ep r o n o u n c e da f t e r1 . 5h o u r s .T h e
damaged cells were not able to be repaired as indicated by
the increase in tail DNA content (Figure 14). Furthermore,
berberine was observed mainly in the cytoplasmic region of
NPC cells at 2 hours of incubation at 200μM as examined
underaﬂuorescentmicroscope(Figure 15).Again,berberine
has been found [158]t ob en e a rt h en u c l e a rr e g i o na n d
able to bind with DNA and may inhibit DNA topoisomerase
II. Therefore, inhibition of DNA repair ability and stability
may also contribute to the cytotoxic eﬀect on the cancer
cells. The DNA damaging eﬀect and the inhibition of
DNA repair contributed to the cytotoxic activity in the
cancer cells may be part of the mechanisms of action of
berberineoncancercells.Berberinealsodisplayedalterations
in cell cycle progression, DNA synthesis, cell proliferation,
and cell death in melanoma cells K1735-M2 mouse and
WM 793 human melanoma malignant cell lines which
were correlated with the concentration and intracellular
distribution of the alkaloid and suggested that it may be
used in clinical development of a cytotoxic compound
[159]. Moreover, berberine was shown to inhibit telomere
elongation [67], and bind to various human G-quadruplex
structures inhibit telomerase [67]. Berberine has been found
to be useful for the treatment of lung cancer patients [160]
and the correlation between the overexpression of AP-I and
lymphatic metastasis has been reported [161]. Combined
treatment with berberine and an anticancer drug camp-
tothecin analogue, CPT-II resulted in a marked inhibition of
the tumor growth at the implantation site and of lymphatic
metastasis, as compared with either treatment alone [162].
Berberine also exhibited dose-dependent antiproliferative
eﬀects of the human promonocytic U937 cells and induced
signiﬁcant changes in mitochondrial membrane potential of
the tumor cells [163]. In a recent study [164], the eﬀects
of berberine on the human promyclocytic leukemia HL60
cells and on the murine mylomonocytic leukemia WEH1-
3 cells suggested berberine induced G2/M arrest in both
the cells via the inhibition of cyclin B1 and the promotion
of Wee1. The treatment of human prostate cancer cells
(PC-3) with berberine revealed that berberine-mediated
cell death of human prostate cancer cells was regulated by
reactive oxygen species and suggested that berberine may be
considered as a promising therapeutic candidate for prostate
cancer [165].
Berberine was assessed for the anti-human cytomega-
lovirus (HCMV) activity using the plaque assay. It was
suggested [166] that berberine inhibited the replication of
HCMV that was presumed to interfere with intracellular
events after virus penetration into the host cells and
before viral DNA synthesis. Berberine showed inhibition
of reverse transcriptase activity of RNA tumor viruses and
the results were correlated with its antileukemic activity
[167]. The enzyme cyclooxygenase-Z (COX-2) is abundantly
expressed in colon cancer cells [168] and plays a key
role in colon tumerogensis [169]. Compounds inhibiting
COX-2 transcriptional activity have therefore potentially
a chemopreventive property against colon tumor forma-
tion. Fukuda et al. [170] have reported that berberine
eﬀectively inhibits COX-2 transcriptional activity in colon
cancer cells in a dose-dependent manner at concentrations
higher than 0.3μM. The inhibitory activity of berberine
on COX-2 promotor activity is not simply due to the
direct inhibition of macromolecular synthesis in the cells.
In addition, reactive oxygen intermediates play a role in the
expression of COX-2 [171] and COX-2 promotor activity is
regulated by interactions of diverse transcription factors and16 Journal of Nucleic Acids
intracellularmessages[172].IthasbeenreportedthatCOX-2
overexpressionisassociatedwiththeacquisitionofresistance
to apoptosis in intestinal epithelial cells [173]. Berberine
exhibits cytostatic and cytocidal eﬀects in various cell lines.
It is likely that inhibition of COX-2 promotor activity may
be associated with antitumor and cytostatic/cytocidal eﬀects
of berberine.
Palmatine has been found in the roots, rhizomes, and
stem bark of many species of berberidaceae, papaveraceae,
fumararaace, menispermaceae, rutaceae, raunculaece,a n d
other plant family. Palmatine has been used as folk medicine
for centuries due to its immense pharmacological properties.
Themedicinalplantscontainingpalmatinehavebeenusedin
the treatment of jaundice, dysentery, hypertension, inﬂam-
mation, and liver diseases [174, 175].
Coralyne has been shown to exhibit signiﬁcant
antileukemic activity against both P388 and l1210 leukemia
cells in mice [74, 176]. Although its antitumor activity is not
very high, coralyne represents a promising lead structure
because of its low toxicity [177, 178]. It was shown that
irradiation of superhelical plasmid DNA in the presence
of coralyne leads to an eﬃcient single-stranded cleavage
even upon exposure to sunlight. Thus photodamaging
properties of coralyne may oﬀer a useful tool for the DNA
damage. Again, the photoinduced cleavage may be used for
the introduction of DNA lesions in triplex and quadruplex
DNA because coralyne exhibits a remarkable propensity to
bind to these higher-order DNA structures [67, 68, 81]. In
particular, the photoinduced damage of the triplex DNA
may be of interest to those therapeutic approaches in which
the selective attack of triplex DNA is the key process.
The quaternary benzophenanthridine alkaloids which
are mainly distributed in the plants of the Papaveraceae,
Rutaceae, Fumariaceae families have been the focus of
increasing attention for their diverse biological activities.
Among this group of alkaloids, sanguinarine possesses
potent anticancer [179–182], promising apoptosis activities
[181], as well as cytotoxic eﬀects [183]. In fact, the plants
containing sanguinarine have been widely used as Chinese
medicines and folk medicines for the treatment of human
cancer and other diseases. In the UK and USA, sanguinarine
has been in use in mouthwashes and toothpastes to inhibit
dentalplaqueandinhibitgingivalhealth[184].Thepotential
anticancer activities of sanguinarine may be attributed to its
binding of chromosomal DNA. Studies have revealed that
in physiological conditions, both iminium and alkanolamine
forms of the alkaloid exist because they all exhibit pH-
dependent structural equilibrium between these two forms
[87, 88, 185]. Alkanolamine form was reported to have
larger cellular availability than iminium form due to its
greater lipophilicity [186]. Maiti et al. [85] studied the
interaction of sanguinarine with B-DNA under various
environmental conditions ie salt molarity, pH, etc. and
suggested that sanguinarine may be useful as a potential
antitumoral agent. This proposal was found to be true
when an in vitro study of cytotoxicity of sanguinarine
using cancer cell lines and primary cells from oral human
tissues established the potential use of sanguinarine for the
inhibition of growth of S-G gingival epithelial cells and KB
carcinoma cells, and correlated with its complex formation
with DNA [137]. Babich et al. [137] studied the eﬀect
of sanguinarine on proliferation of the S-G cells exposed
for 1 to 3 days as shown in Figure 16. It was noted that
linear increase in growth was signiﬁcantly aﬀected with
increasing concentration of sanguinarine and no growth
was observed after 3 days of exposure to sanguinarine
at 5.1μM or greater concentration. As assessed by DNA
quantiﬁcation,S-G-cellsmaintainedcontinuouslyinhibition
of growth increasing concentration of sanguinarine from
1.7μMt o8 . 5μM may reﬂect the ability of sanguinarine to
intercalate DNA. Sanguinarine has been reported to possess
the potential for selective/preferential elimination of cancer
cells without aﬀecting normal cells [180, 187]. The study of
diﬀerential eﬀects [188] of the alkaloid upon cell viability,
DNA damage, and nucleus integrity in mouse primary
spleen cells and mouse lymphocytic leukemic cells L1210
showed that sanguinarine produces dose-dependent increase
in DNA damage and cytotoxicity in both cells. In contrast
to primary mouse spleen cells, leukemic L1210 cells showed
slightly higher sensitivity to sanguinarine, suggesting that
cytotoxic and DNA damaging eﬀects of sanguinarine are
more selective against mouse leukemic cells and primary
mouse spleen cells [188]. Han et al. [189] investigated the
possible mechanism through which sanguinarine exerts its
antiproliferative action in cultured rat glioblastoma cells
and suggested the induction of apoptosis to be due to
the downregulation of the extra cellular signal regulated
kinase and Akt signaling pathway. The eﬀect of sanguinarine
on the human cells line HeLa (Cervix carcinoma cells)
has been studied [190] and the results showed a strong
killing eﬀect of sanguinarine which was explained as a
consequence of its easy penetration through cell membrane
owing to nonpolar pesudobase formation and to a high
degree of molecular planarity. Primary eﬀusion lymphoma
[PEL] is an incurable, aggressive B-cell malignancy that
develops rapid resistance to conventional chemotherapy.
It was established [191] that sanguinarine inhibits cell
proliferation and induces apoptosis in a dose dependent
manner in several PEL cell lines and suggested that the
alkaloid is a potent inducer of apoptosis of PEL cells via
upregulation of death receptor 5 and raise the possibility
that sanguinarine may be of value in the development of
novel therapeutic approaches for the treatment of PEL cells.
To investigate sanguinarine sensitivity in neuroendocrine
tumor cell lines (human pancreatic carcinoid and human
bronchial carcinoid cells), Larsson et al. reported [192]
that these tumor cell lines are very much sensitive to
sanguinarine, which may be used, in clinical trials and show
therapeutic eﬀect in patients with neuroendocrine tumors.
A recent study showed [193] that treatment of human breast
cancerMDA-231cellswithsanguinarineinducedremarkable
apoptosis accompanying the generation of reactive oxygen
species leading to cell death. Very recently Matkar et al.
[194] studied the eﬀect of sanguinarine in human colon
cancer cell-line and showed its ability to cause DNA single
and double stranded break as well as increased level of 8-
oxodeoxyguanosine and reported DNA damage consistent
with colon cancer cell death.Journal of Nucleic Acids 17
5. Conclusions andPerspectives
Theuseofplantsasmedicinesbyhumandatesbacktoseveral
thousand years. Alkaloids of plant origin are natural prod-
ucts that exhibit a myriad of biological and pharmacological
properties. In view of their extensive occurrence in nature
and signiﬁcantly low toxicities, prospective development and
use of these alkaloids as anticancer drugs are matters of great
current interest. This review has focused on nucleic acid
binding properties and topoisomerase inhibitory activities
of some important representatives of the protoberberine
(berberine, palmatine, and coralyne) and benzophenanthri-
dine (sanguinarine) groups of alkaloids and their derivatives
in relation to their role in cancer.
A large amount of published data suggests that all these
alkaloids bind to various polymorphic DNA and also to
single stranded poly(A) structures as evidenced from diverse
biophysical techniques. Berberine and palmatine bind to
the B-form DNA by partial intercalation. On the other
hand, berberine binds to left-handed Hoogsteen base paired
HL-form DNA suggesting the eﬀective use of berberine as
sensitive probes to detect handedness change in DNA on
protonation but it does not bind to left-handed Watson-
Crick base paired Z-form. Coralyne on the other hand
exhibits strong binding to duplex B-form DNA and single
stranded poly(A) structure by mechanism of intercalation
as well as it induces self-structure formation on binding
to single stranded poly(A). Again, berberine and coralyne
have the ability to induce and stabilize DNA triplexes and
G-quadruplex structures (including human G-quadruplex)
as well. Their eﬃciency in inhibiting telomerase and topoi-
somerase activity may potentiate their use as potential
anticancer drugs. The alkaloid sanguinarine is known for its
anticancer/antitumor properties and possesses the potential
for selective/preferential elimination of cancer cells. It binds
toB-formduplexDNAandsinglestrandedpoly(A)structure
very strongly by intercalation and it induces the conversion
of single stranded poly(A) to double-stranded poly(A) on
binding. Sanguinarine does not bind to Z-form or HL-
f o r mb u ti tc o n v e r t sb o t hZ - f o r ma n dH L-form DNA to
bound B-form structure. It also formed a strong complex
with triplex DNA that may lead to its use in triplex-
targeted cancer therapy. Sanguinarine has been shown to
stabilized the intramolecular DNA G-quadruplex formed in
human teleomeric sequence (tandem d(TTAGGG) repeats)
and to inhibit the activity of telomerase and teleomere
maintenance. Thus, sanguinarine may be considered as a
useful molecule for cancer therapeutic action. The striking
aspect here is that the speciﬁc binding of all these alkaloids
to single-stranded adenine regions of the mRNA-poly(A)
tail could interfere in mRNA processing by human PAP to
be signiﬁcantly overexpressed in human cancer cells and
m a ye m e r g ea sn e wt y p eo fR N Ab a s e dt h e r a p e u t i ca g e n t s
for cancer diseases. Thus, the diﬀerential binding of these
alkaloids to various polymorphic nucleic acid conformations
with speciﬁc biological functions may potentiate their use in
nucleic acid-targeted drug design that in turn may convey
some speciﬁc meaning for their regulatory roles in neoplastic
diseases.
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